- €111.54m
- €88.56m
- €248.14m
Brief: Haemato Says Terminates Cooperation With Korean Manufacturer Huons Biopharma; To Discontinue Project For A Proprietary Botulinum Toxin
Brief: Haemato Q1 EBITDA At EUR 2.3 Mln
Brief: Haemato To Propose Dividend Of EUR 1.10 Per Share
Brief: Haemato Preliminary Consolidated FY EBIT Up At EUR 11.2 Mln
Brief: Expansion Of Haemato's Executive Board
Brief: Haemato 9-Month Revenues Up At EUR 216.6 Mln
Brief: Haemato Seeks Marketing Authorization And Plans Distribution Of Botulinum Toxin Product In Europe
Brief: Haemato Preliminary Q2 EBIT Up At EUR 4.8 Million
Brief: Haemato Q1 EBIT Up At EUR 2.4 Mln
Brief: Haemato To Propose Dividend Of EUR 1.00 Per Dividend-Bearing Share
Brief: MPH Health Care FY Net Loss At EUR 70.4 Mln
Brief: Haemato FY EBITDA Up 74.8% At EUR 3.3 Mln
Brief: Haemato Completes Capital Increase
Brief: Haemato Plans Cash Capital Increase To Finance Private Label Business
Brief: Haemato Pharm GmbH Received Approval For Antigen Rapid Test For Self-Testing By Laypersons
Brief: Haemato Patrick Brenske To Be Sole Member Of Executive Board
Brief: M1 Kliniken Sells Unit M1 Aesthetics GmbH To Haemato
Brief: Haemato buys M1 GmbH
Brief: Haemato Expansion Of Executive Board